-- Results demonstrate potential of MultiTAA-specific T cell therapy in combination with chemotherapy as a first-line treatment option for patients with advanced or metastatic pancreatic adenocarcinoma--
-- Evidence of epitope-spreading was observed in all responders, suggesting that MultiTAA T cell therapy triggered the recruitment of a broader endogenous immune system response--
-- Company to host investor event and webcast on Monday, June 1 at 8:00am EDT--
PR Newswire
HOUSTON, May 29, 2020